| HRA004337
(Controlled Access)
|
PD-1 blockade plus chemotherapy has become the new standard of care in patients with untreated advanced non-small-cell lung cancer (NSCLC), whereas predictive biomarkers remain unknown. Here, we integrated clinical and HLA class I (HLA-I) genotype data of 427 NSCLC patients treated with first-line PD-1 blockade plus chemotherapy or chemotherapy from two previously reported phase 3 trials and investigated the predictive value of HLA-I evolutionary divergence (HED). HED could predict improved response rates and survival outcomes in patients treated with PD-1 blockade plus chemotherapy but not chemotherapy in both two trials, and its predictive value held in multivariate analysis when adjusted for PD-L1 expression and tumor mutation burden. |
